151
Participants
Start Date
December 28, 2017
Primary Completion Date
August 23, 2021
Study Completion Date
April 28, 2023
Dabrafenib
Dabrafenib was available as 50 mg and 75 mg hard capsules and as 10 mg dispersible tablets for oral suspension. Dabrafenib was administered orally, twice daily, and was dosed based on age and weight Patients \< 12 years old and ≥ 16 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥ 12 years old and ≥ 19 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day) Patients \< 12 years old and \< 16 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥12 years old and \<19 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day)
trametinib
"Trametinib was available as 0.5 mg and 2 mg film-coated tablets and as 5.0 mg powder in bottle for oral solution (0.05 mg/ml after reconstitution with 90 ml water).Trametinib was administered orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on age and weight.~Patients \<6 years old and \<26 kg were to be administered the trametinib oral solution (dose: 0.032 mg/kg/day) Patients \<6 years old and ≥26 kg were to be administered either the trametinib oral solution or trametinib tablets (dose: 0.032 mg/kg/day) Patients ≥6 years old and ≥10 kg \< 33 kg were to be administered the trametinib oral solution (dose: 0.025 mg/kg/day) Patients ≥6 years old and ≥33 kg were to be administered either the trametinib oral solution or the trametinib tablets (dose: 0.025 mg/kg/day)"
Carboplatin
"Carboplatin was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Carboplatin was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy. Each maintenance cycle was 6 weeks, and consisted of 4 weeks of chemotherapy with 2 weeks of rest.~Induction: 175 mg/m\^2 as weekly intravenous (IV) infusion on weeks 1 to 4, and on weeks 7 to 10, on the same day as vincristine dosing Maintenance: 175 mg/m\^2 as weekly IV infusion over 60 minutes on weeks 1 to 4 of each cycle."
Vincristine
"Vincristine was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Vincristine was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy.~Induction: 1.5 mg/m\^2 as weekly IV bolus infusion (0.05 mg/kg if child is \<12 kg) (maximum dose of 2.0 mg) for 10 weeks.~Maintenance: 1.5 mg/m\^2 as weekly IV bolus infusion (0.05 mg/kg if child is \<12 kg) (maximum dose of 2.0 mg) on weeks 1 to 3 of each cycle, on the same day as carboplatin dosing."
Novartis Investigative Site, Randwick
Novartis Investigative Site, Parkville
Novartis Investigative Site, Utrecht
Novartis Investigative Site, Zurich
Novartis Investigative Site, Torino
Novartis Investigative Site, Berlin
Novartis Investigative Site, Genova
Novartis Investigative Site, Stockholm
Childrens National Hospital, Washington D.C.
Novartis Investigative Site, Milan
Novartis Investigative Site, Hamburg
Johns Hopkins University IDS Pharmacy John Hopkins Hospital, Baltimore
Novartis Investigative Site, Madrid
Novartis Investigative Site, Toulouse
Nicklaus Childrens Hospital, Miami
Novartis Investigative Site, Tampere
Novartis Investigative Site, Göttingen
St Jude Children's Research Hospital, Memphis
Novartis Investigative Site, Essen
Novartis Investigative Site, Valencia
Novartis Investigative Site, Petah Tikva
Novartis Investigative Site, Florence
Novartis Investigative Site, Cologne
Novartis Investigative Site, Tel Litwinsky
Novartis Investigative Site, Lille
Ann and Robert H Lurie Childrens Hospital of Chicago ., Chicago
Washington University School of Medicine SC, St Louis
Novartis Investigative Site, Strasbourg
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, Lyon
Novartis Investigative Site, Paris
Texas Children s Hospital Baylor College of Medicine, Houston
Novartis Investigative Site, Augsburg
Children's Hospital of Orange County, Orange
Novartis Investigative Site, Villejuif
Novartis Investigative Site, Moscow
Indiana University School of Medicine ., Indianapolis
Cincinnati Childrens Hospital Medical Center Cancer & Blood Disease Inst., Cincinnati
Novartis Investigative Site, CABA
Novartis Investigative Site, Brussels
Novartis Investigative Site, Barretos
Novartis Investigative Site, São Paulo
Novartis Investigative Site, São Paulo
Novartis Investigative Site, Vancouver
Novartis Investigative Site, Toronto
Novartis Investigative Site, Montreal
Novartis Investigative Site, Brno
Novartis Investigative Site, Prague
Novartis Investigative Site, Copenhagen
Novartis Investigative Site, Roma
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Setagaya-ku
Novartis Investigative Site, Osaka
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Leeds
Novartis Investigative Site, Liverpool
Novartis Investigative Site, London
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY